The company will now be able to market the test, which algorithmically weighs molecular markers and clinical information, in all 50 US states.
Metascape uses data from over 40 knowledgebases and 10 model organisms to provide functional enrichment, interactome analysis, gene annotation, and membership search capabilities.
The group published results showing its method can faithfully recapitulate genome-wide measures of DNA repair deficiency using much smaller sequencing panels.
The study used a variety of sequencing and mapping technologies, including from Illumina, Pacific Biosciences, 10X Genomics, Bionano Genomics, and Oxford Nanopore.
The St. Louis-based firm will offer a sequencing service to help researchers separate target signals from errors made during next-generation sequencing.
In Science this week: the synthetic genetic system hachimoji, and more.
IBM and the Broad Institute will codevelop algorithms to apply artificial intelligence to predict cardiovascular risk from genomic and clinical data.
The machine-learning-based method identifies relationships between bacterial strains and tracks their movements in less time, using less memory than existing solutions.
The solution uses machine learning to pare down somatic variant lists, simplifying the task of manually reviewing the output of sequence analysis pipelines.
The company has not released data on its method, but describes a circulating tumor DNA approach that has similarities to what other firms are pursuing.
The US National Institutes of Health's All of Us project awarded $4.6 million to the company Color to develop a genetic counseling resource for the program.
The Times of India reports on a pilot study that used genomic testing to determine whether patients had drug-resistant tuberculosis.
New guidelines say that more women may benefit from genetic testing for hereditary breast or ovarian cancer, according to the Los Angeles Times.
In Cell this week: small proteins identified among human microbiome, role for tumor microbes in pancreatic cancer survival, and more.